CN107361360A - A kind of composition and its application - Google Patents
A kind of composition and its application Download PDFInfo
- Publication number
- CN107361360A CN107361360A CN201710606032.XA CN201710606032A CN107361360A CN 107361360 A CN107361360 A CN 107361360A CN 201710606032 A CN201710606032 A CN 201710606032A CN 107361360 A CN107361360 A CN 107361360A
- Authority
- CN
- China
- Prior art keywords
- composition
- medicine
- composition according
- application
- female
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 18
- 235000013402 health food Nutrition 0.000 claims abstract description 15
- 230000035558 fertility Effects 0.000 claims abstract description 13
- 210000000287 oocyte Anatomy 0.000 claims abstract description 11
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 10
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 10
- 230000002611 ovarian Effects 0.000 claims abstract description 10
- 210000004681 ovum Anatomy 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 7
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 6
- 241000220317 Rosa Species 0.000 claims description 5
- 229940087603 grape seed extract Drugs 0.000 claims description 5
- 235000002532 grape seed extract Nutrition 0.000 claims description 5
- 239000001717 vitis vinifera seed extract Substances 0.000 claims description 5
- 241000628997 Flos Species 0.000 claims description 4
- 241000219095 Vitis Species 0.000 claims description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 4
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 229930003944 flavone Natural products 0.000 claims 1
- 150000002213 flavones Chemical class 0.000 claims 1
- 235000011949 flavones Nutrition 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- ZUQUTHURQVDNKF-KEWYIRBNSA-N 1-[(3R,4R,5S,6R)-3-amino-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]ethanone Chemical class CC(=O)C1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N ZUQUTHURQVDNKF-KEWYIRBNSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Chemical group CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 8
- 208000000509 infertility Diseases 0.000 description 8
- 230000036512 infertility Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 6
- 231100000535 infertility Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010021928 Infertility female Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 208000021267 infertility disease Diseases 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000625 blastula Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical group C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to field of health care food, more particularly to a kind of composition and its application.N acetylglucosamines, composition, medicine or health food provided by the invention can adjust female endocrinic disorders, improve ovarian function, improve oocyte quality, promote the combination of sperm and ovum, improve female fertility, therefore can receive promising result.
Description
Technical field
The present invention relates to field of health care food, more particularly to a kind of composition and its application.
Background technology
Infertility is referred to as female sterility caused by female factors, female sterility be a kind of incidence of disease compared with
High and more refractory illness more.Research data shows at present both at home and abroad：The incidence of disease of the infertility in child-bearing period Mr. and Mrs is about
For 15%-20%, counted according to the World Health Organization：The whole world about 600-8000 ten thousand suffers from different degrees of infertility to Mr. and Mrs
Disease, wherein infertility accounts for the 50% of all infertile couples as caused by female factors.Female fertility is in the increase at age
Downward trend, the probability being pregnant in 1 year can reach 90% at 20 years old, and be only 36.4% at 40 years old or so.Chinese population base
Number is big, and the opening of two child's policies in recent years, there is that the advanced age Mr. and Mrs of fertility demand are more and more, and the incidence of disease of sterility is in recent years
Also it is in rising trend.Sterility often results in goodwill as between spouses discord, marriage and family rupture, destabilizing factor is brought to society.Female
Property infertility the cause of disease it is varied, most directly show as endocrine disturbance, premature ovarian failure, oocyte quality decline.
China's pharmaceutical technology field have accumulated more rich experience in terms of female sterility is treated at present, have doctor trained in Western medicine to control
Treat, such as using medicine, operation, also there are many effective Chinese patent drugs, although these treatment methods are each in terms of sterility is treated
There is its advantage, but every kind of method all has some limitations.And the drug therapy duration is grown, and with numerous secondary works
With operative treatment wound is big.And due to the tradition of the Chinese nation, people are more willing to prioritizing selection tonic.A kind of therefore it provides effect
Fruit is notable, has no side effect, and can adjust female endocrinic disorders, improves ovarian function, improves oocyte quality, improves female fertility
The health food of ability has important practical significance.
The content of the invention
In view of this, the invention provides a kind of composition and its application, said composition is scientific and effective, nothing
Side effect, female endocrinic disorders can be adjusted, improve ovarian function, improve oocyte quality, improve female fertility
The health food of ability.
In order to realize foregoing invention purpose, the present invention provides following technical scheme：
The invention provides 2-Acetamido-2-deoxy-D-glucose to prepare regulation female endocrinic disorders, improvement ovarian function, carry
Application in the medicine or health food of the combination of high oocyte quality, promotion sperm and ovum.
Present invention also offers 2-Acetamido-2-deoxy-D-glucose to prepare the medicine or health food of raising female fertility
In application.
Present invention also offers a kind of composition, including 2-Acetamido-2-deoxy-D-glucose, rose and grape pip.
In some specific embodiments of the present invention, the rose is Flos Rosae Rugosae extract, and the grape pip is grape
Seed extract.
The present invention some specific embodiments in, the 2-Acetamido-2-deoxy-D-glucose, the Flos Rosae Rugosae extract and
The mass ratio of the grape seed extract is (300~7500):(12~300):(48~1200).
In other specific embodiments of the present invention, the 2-Acetamido-2-deoxy-D-glucose, the Flos Rosae Rugosae extract
Mass ratio with the grape seed extract is 1500:60:240.
In some specific embodiments of the present invention, the composition also includes Co-Q10, folic acid, isoflavones
Or mixture more than one or both of Bulbus Lilii extract.
In some specific embodiments of the present invention, in terms of mass parts, the composition includes following component：
In some specific embodiments of the present invention, in terms of mass parts, the composition includes following component：
In some specific embodiments of the present invention, in terms of mass parts, the composition includes following component：
In some specific embodiments of the present invention, in terms of mass parts, the composition includes following component：
In some specific embodiments of the present invention, in terms of mass parts, the composition includes following component：
In some specific embodiments of the present invention, in terms of mass parts, the composition includes following component：
In some specific embodiments of the present invention, in terms of mass parts, the composition includes following component：
In some specific embodiments of the present invention, in terms of mass parts, the composition includes following component：
Present invention also offers described composition to prepare regulation female endocrinic disorders, improve ovarian function, raising
Application in the medicine or health food of the combination of oocyte quality, promotion sperm and ovum.
Present invention also offers described composition in the medicine or health food that improve female fertility is prepared
Using.
Tablet is made after auxiliary material is added for the composition of the present invention or medicine or health food, instructions of taking is made in capsule
For：Orally, one at a time, 1 times a day, a clothes (or following the doctor's advice) from morning.Each course for the treatment of 30 days.The lighter takes the 1-2 course for the treatment of, severe one
Take the 3-4 course for the treatment of.
Composition, medicine or health food provided by the invention can adjust female endocrinic disorders, improve ovarian function,
Oocyte quality is improved, promotes the combination of sperm and ovum, improves female fertility, therefore promising result can be received.
Embodiment
The invention discloses a kind of composition and its application, those skilled in the art can use for reference present disclosure, suitably change
Enter technological parameter realization.In particular, all similar replacements and change are aobvious for a person skilled in the art
And be clear to, they are considered as being included in the present invention.The method of the present invention and application are carried out by preferred embodiment
Description, related personnel can substantially not depart from present invention, method described herein and application carried out in spirit and scope
Change is suitably changed with combining, to realize and using the technology of the present invention.
Raw materials used and reagent can be bought by market in a kind of composition provided by the invention and its application.
With reference to embodiment, the present invention is expanded on further：
Embodiment 1
Each composition presses following dosimetric system into capsule：
Daily 1, a clothes, 30 days as one therapeutic course, takes 3 courses for the treatment of altogether from morning.
Embodiment 2
Each composition presses following dosimetric system into capsule：
Daily 1, a clothes, 30 days as one therapeutic course, takes 2 courses for the treatment of altogether from morning.
Embodiment 3
Each composition presses following dosimetric system into capsule：
Daily 1, a clothes, 30 days as one therapeutic course, takes 4 courses for the treatment of altogether from morning.
Embodiment 4
Each composition presses following dosimetric system into capsule：
Daily 1, a clothes, 30 days as one therapeutic course, takes 3 courses for the treatment of altogether from morning.
Embodiment 5
Each composition presses following dosimetric system into capsule：
Daily 1, a clothes, 30 days as one therapeutic course, takes 3 courses for the treatment of altogether from morning.
Embodiment 6
Each composition presses following dosimetric system into capsule：
Daily 1, a clothes, 30 days as one therapeutic course, takes 2 courses for the treatment of altogether from morning.
Embodiment 7
Using the female CD-1 mouse of 8 weeks after 40 births, 4 groups are randomly divided into, every group 10, respectively control group, a left side
Revolve Capsules group prepared by carnitine group, N-GlcNAc groups and the embodiment of the present invention 1.Control group is left-handed only by body weight feeding distilled water
Carnitine group feeds 0.4mg l-cns, and N-GlcNAc groups feed 25 μ g/kg N-GlcNAc by body weight, and the embodiment of the present invention 1 is made
Standby Capsules group by mouse weight feeding ovum again can compound 10mg/kg, promote super row using promoting super drug row thing after feeding 3 weeks, by
Egg cell is collected after mouse euthanasia, assesses the quality and quantity of egg cell, and it forms capsule using experimental evaluation in vitro fertilization
The ability of embryo.
Experimental result is shown in Table 1.
Table 1
* show has significant difference (P ＜ 0.05) compared with control group
From the result of table 1, in terms of egg cell degradation ratio, compared with control group, there is notable (P in l-cn group
＜ 0.05) decline, Capsules group prepared by N-GlcNAc groups and the embodiment of the present invention 1 equally occurs notable (P ＜ 0.05)
Decline.Capsules group prepared by the embodiment of the present invention 1 is compared with N-GlcNAc groups compared with l-cn group, in the presence of egg cell degradation ratio
Drop trend.Illustrate that capsule prepared by N-GlcNAc and the embodiment of the present invention 1 can significantly improve the ratio of high-quality egg cell, and
Effect is better than l-cn, and composition group effect prepared by the embodiment of the present invention 1 is better than N-GlCNAc groups.
In terms of blastocyst rate, compared with control group, there is the rising of notable (P ＜ 0.05), N- in l-cn group
Equally there is the rising of notable (P ＜ 0.05) in composition group prepared by GlcNAc groups and the embodiment of the present invention 1.The present invention is implemented
Capsules group prepared by example 1 is compared with N-GlcNAc groups compared with l-cn group, and the ratio that egg cell forms blastaea has ascendant trend.
Illustrate that capsule prepared by N-GlcNAc and the embodiment of the present invention 1 can significantly improve egg cell development to the ratio of blastula stage,
And effect is better than l-cn, ovum can organize effect and be better than N-GlCNAc groups again.
The capsule for taking the embodiment of the present invention 1,3~6 to prepare carries out above-mentioned experiment, the group that result of the test is prepared with embodiment 1
Compound is without significant difference (P ＞ 0.05).Illustrate that composition provided by the invention significantly (P ＜ 0.05) can improve high-quality egg cell
Ratio, notable (P ＜ 0.05) improves egg cell development to the ratio of blastula stage
Embodiment 8
In order to prove that composition provided by the invention, medicine or the effect of health food, 2015-2016, applicant make
Clinical test is carried out with the embodiment of the present invention 2, treats sterile female patient 60 after marriage, evident in efficacy, particulars are as follows.
Data：60 are atocia special outpatient clinic patient, and diagnosis meets following standard：The couple at child-bearing age, there is normality
Life, do not take contraceptives not educate within more than 2 years (exclude bridegroom's or husband's side factor), exclusion obstruction of fallopian tube, other endocrine system diseases,
The organic diseases such as severe genitor road deformity.At 23~44 years old age, average age 33.6 years old, the course of disease was at 2 years~14 years.
Diagnostic criteria：Female infertility diagnosis and the guide assessed with reference to ASRM committees issue in 2015.
Treatment method：Using this health food, instructions of taking is：Orally, once a grain, once a day, pause clothes.It is each to treat
Journey 30 days.The lighter takes the 1-2 course for the treatment of, and severe one takes the 3-4 course for the treatment of and judges curative effect.
Curative effect determinate standard
Recovery from illness：Symptom disappears, wife's side pregnancy.
It is effective：Wife's side unpregnancy, endocrine disturbance symptom are clearly better.
Effectively：Endocrine disturbance symptom takes a turn for the better earlier above.
It is invalid：Clinical symptoms are without significant change, unpregnancy.
As a result：
Comprehensive therapeutic effect：Fully recover 28 (46.7%), effective 20 (33.3%), effective 8 (13.3%), invalid 4
(6.7%), total effective rate 93.3%.
Model case：
Example 1, female, 32 years old, worker, Chongqing Beiren, in first visit in July, 2015.To get married 4 years, the bridegroom's or husband's side checks normally, but
Do not become pregnant.Ovulation tests ovulation is irregular.It is oral to give invention formulation, once a grain, 1 times a day, a clothes, each course for the treatment of 30
My god.Ovulation tests are checked after 2 courses for the treatment of, earlier above rule.Continue a course for the treatment of of taking medicine, be pregnant in December, 2015.
Example 2, female, 36 years old, office worker, Chongqing City people from Fuling, the first visit of in August, 2015.Get married 4 years and do not educate, the bridegroom's or husband's side checks and had no
It is obvious abnormal.Serum FSH and estradiol measure show ovarian failure.Patient takes 3 courses for the treatment of of invention formulation, checks serum
FSH and estradiol measure, display ovarian function take a turn for the better.Continue to take 2 courses for the treatment of of this preparation again afterwards.Follow-up in June, 2016, has cherished
Pregnant March.
The capsule provided using the embodiment of the present invention 1,3~6 carries out above-mentioned experiment, and result of the test provides with embodiment 2
Capsule effect is close, no significant difference (P ＞ 0.05).Understand, composition, medicine or health food provided by the invention can be adjusted
Female endocrinic disorders are saved, improve ovarian function, improve oocyte quality, promotes the combination of sperm and ovum, significantly improves women
Fecundity.
It can be seen that effect of the present invention is notable, there is advantages below：(1) curative effect is preferable, and it is disorderly that female incretion is adjusted after taking
Disorderly, improve ovarian function, improve oocyte quality, promote the combination of sperm and ovum, improve female fertility.2) scope of application
Extensively, suitable for various age groups, especially to having good therapeutic effect because age increase causes fecundity to decline, and without obvious pair
Effect.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1.N- acetylglucosamines are preparing regulation female endocrinic disorders, are improving ovarian function, raising oocyte quality, rush
The application entered in the medicine or health food of the combination of sperm and ovum.
Application of the 2.N- acetylglucosamines in the medicine or health food that improve female fertility is prepared.
3. a kind of composition, it is characterised in that including 2-Acetamido-2-deoxy-D-glucose, rose and grape pip.
4. composition according to claim 3, it is characterised in that the rose is Flos Rosae Rugosae extract, the grape pip
For grape seed extract.
5. composition according to claim 4, it is characterised in that the 2-Acetamido-2-deoxy-D-glucose, the rose carry
It is (300~7500) to take the mass ratio of thing and the grape seed extract:(12~300):(48~1200).
6. according to the composition described in any one of claim 3 to 5, it is characterised in that also different including Co-Q10, folic acid, soybean
Mixture more than one or both of flavones or Bulbus Lilii extract.
7. composition according to claim 5, it is characterised in that in terms of mass parts, including following component：
8. composition according to claim 5, it is characterised in that in terms of mass parts, including following component：
9. the composition according to any one of claim 3 to 8 is preparing regulation female endocrinic disorders, is improving ovary work(
Application in the medicine or health food of the combination that, oocyte quality, promotion sperm and ovum can be improved.
10. the composition according to any one of claim 3 to 8 is preparing the medicine for improving female fertility or health care food
Application in product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710606032.XA CN107361360A (en) | 2017-07-24 | 2017-07-24 | A kind of composition and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710606032.XA CN107361360A (en) | 2017-07-24 | 2017-07-24 | A kind of composition and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107361360A true CN107361360A (en) | 2017-11-21 |
Family
ID=60307547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710606032.XA Pending CN107361360A (en) | 2017-07-24 | 2017-07-24 | A kind of composition and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107361360A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109620951A (en) * | 2018-12-28 | 2019-04-16 | 丽睿客信息科技（北京）有限公司 | One kind helping pregnant composition and preparation method thereof |
| CN118104819A (en) * | 2024-04-30 | 2024-05-31 | 成都初因科技有限公司 | Composition for ovarian health care and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040156923A1 (en) * | 2002-10-23 | 2004-08-12 | Davenport David F. | Method and nutraceutical composition for mammals |
| CN101991523A (en) * | 2010-05-19 | 2011-03-30 | 黄汉贤 | Specific anti-wrinkle whitening cream and preparation method thereof |
| CN104198707A (en) * | 2014-09-12 | 2014-12-10 | 范飞舟 | Application of N-acetylglucosamine in preparing kit for detecting tumor |
| WO2015173839A1 (en) * | 2014-05-14 | 2015-11-19 | Haskoli Islands | A peptide or protein stabilizing formulation |
-
2017
- 2017-07-24 CN CN201710606032.XA patent/CN107361360A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040156923A1 (en) * | 2002-10-23 | 2004-08-12 | Davenport David F. | Method and nutraceutical composition for mammals |
| CN101991523A (en) * | 2010-05-19 | 2011-03-30 | 黄汉贤 | Specific anti-wrinkle whitening cream and preparation method thereof |
| WO2015173839A1 (en) * | 2014-05-14 | 2015-11-19 | Haskoli Islands | A peptide or protein stabilizing formulation |
| CN104198707A (en) * | 2014-09-12 | 2014-12-10 | 范飞舟 | Application of N-acetylglucosamine in preparing kit for detecting tumor |
Non-Patent Citations (3)
| Title |
|---|
| 吴凌: "《养好卵巢不病不老》", 31 May 2017, 科学技术文献出版社 * |
| 杨思利，等: "《临床常用药物》", 30 November 1998, 山东科学技术出版社 * |
| 陈瑞: "《卵巢养好 女人才好》", 31 August 2014, 湖北科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109620951A (en) * | 2018-12-28 | 2019-04-16 | 丽睿客信息科技（北京）有限公司 | One kind helping pregnant composition and preparation method thereof |
| CN118104819A (en) * | 2024-04-30 | 2024-05-31 | 成都初因科技有限公司 | Composition for ovarian health care and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019203448B2 (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| Dugoua et al. | Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation | |
| Bowers Jr et al. | Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment | |
| CN107361360A (en) | A kind of composition and its application | |
| Kathpalia | Early maternal feeding versus traditional delayed feeding after cesarean section: a pilot study | |
| Hosomi et al. | Effects of chronic Bryophyllum pinnatum administration on Wistar rat pregnancy | |
| CN104027339A (en) | Vitamin composition and application thereof in regulating ovarian function | |
| CN107927790A (en) | A kind of composition and its application | |
| CN108553495A (en) | A kind of antitumor Chinese medicine composition, active ingredient compositions and application thereof and preparation | |
| De Frène et al. | Gonadotropin therapy versus laparoscopic ovarian drilling in clomiphene citrate-resistant polycystic ovary syndrome patients: a retrospective cost-effectiveness analysis | |
| WO2024060834A1 (en) | Use of fluoropyridoxal in preparing medicament against cancer | |
| CN109045162B (en) | Traditional Chinese medicine composition for treating endometriosis and application thereof | |
| Askew | Zolpidem Addiction in a Pregnant Woman with a History of Second‐Trimester Bleeding | |
| Hamed et al. | Comparison between oral zinc and agar with phototherapy in the treatment of neonatal jaundice: A prospective clinical trial study | |
| Baka et al. | The effect of nefopam on lactation after caesarean section: a single-blind randomised trial | |
| Serrano et al. | Prospective safety study of immunotherapy administered in a cluster schedule | |
| Wisner et al. | Psychotropic drugs | |
| CN109966498A (en) | A kind of medical composition and its use of depression | |
| Goyal et al. | Galactorrhea and amenorrhea in burn patients | |
| CN107412240A (en) | A kind of composition and its application | |
| ABDELSATTAR et al. | Comparative Study between Cervical Cerclage and Progesterone for Preventing Pre-Term Labour in Women with History of Pre-Term Labour | |
| CN101757162A (en) | Traditional Chinese medicine preparation for treating asthenozoospermia | |
| Utian | Recent developments in pharmacotherapy for vasomotor symptoms | |
| Parveen et al. | Testo Induced ovulation successfully in women of polycystic ovarian syndrome | |
| Petrányi et al. | Five-year treatment experience with metformin in polycystic ovary syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171121 |